Aligos Therapeutics (ALGS) 8th Annual MASH Investor Conference summary

Company overview and pipeline

• Focuses on viral and liver diseases, with lead programs in chronic hepatitis B (HBV) and MASH.

• HBV program centers on ALG-00184, a capsid assembly modulator (CAM) with enhanced potency and liver uptake.

• Additional pipeline includes a MASH compound and a pan-coronavirus protease inhibitor funded externally.

Differentiation and mechanism of lead HBV compound

• ALG-00184 demonstrates high oral absorption and liver accumulation, enabling dual mechanisms of action.

• Blocks both HBV DNA replication and cccDNA replenishment, unlike nucleoside analogues.

• No drug resistance observed out to 72 weeks, with marked reductions in HBV DNA, RNA, and antigens.

Regulatory and clinical strategy

• Pursues chronic suppression as the regulatory pathway, validated by international guidelines and regulatory feedback.

• Not targeting functional cure due to limited patient applicability and lack of durable response in prior approaches.

• Therapy designed to benefit all HBV patients, regardless of antigen status or viral load.